Draft Genome Sequence of a Multidrug-Resistant Acinetobacter baumannii Strain from Chile by Opazo, Andrés et al.
Draft Genome Sequence of a Multidrug-Resistant Acinetobacter
baumannii Strain from Chile
Andrés Opazo,a,b Bruno S. Lopes,a,c Patricia García,d Mariana Domínguez Yévenes,b Celia Lima,b Helia Bello-Toledo,b
Gerardo González-Rocha,b Sebastian G. B. Amyesa
Medical Microbiology, The Chancellor’s Building, University of Edinburgh, Edinburgh, United Kingdoma; Laboratorio de Investigación en Agentes Antibacterianos,
Facultad de Ciencias Biológicas, Departamento de Microbiología, Universidad de Concepción, Concepción, Chileb; Department of Microbiology, School of Medicine and
Dentistry, University of Aberdeen, Aberdeen, United Kingdomc; Laboratorio de Microbiología, Departamento de Laboratorios Clínicos, Escuela de Medicina, Pontificia
Universidad Católica de Chile, Santiago, Chiled
Acinetobacter baumannii strain Ab5 was isolated in the year 2007 in Chile, being one of the first multidrug-resistant (MDR)
cases reported in the country. Here, we present the very first draft genome sequence of anMDRChilean strain, which shows the
presence of diverse resistance and acquired virulence genes.
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Acinetobacter baumannii is a nosocomial pathogen normallyclassified as multidrug resistant (MDR). Alarmingly, the
number of MDR A. baumannii isolates has increased in the last
few years, making it a difficult microorganism to treat (1, 2), as
infections caused by it are associated with high rates of mortality
and long periods of hospitalization (3). The rates of Acinetobacter
species MDR isolates in Latin America have increased lately, as
resistance to imipenem in Chile increased from 0.0% during 1997
to 1999, to 47.4% in the 2008 to 2010 period (4), and 65.8% in
2014 (Antibiotic Resistant Group from Chilean Society for Infec-
tious Diseases, personal communication).
In this work, we studied the genetic features of the A. bauman-
nii MDR strain Ab5 through whole-genome sequencing (WGS), as
this was one of the first sentinel cases of MDR isolates in Chile. To
date, there are no whole-genome sequences of A. baumannii strains
from Chile available in GenBank. The Ab5 strain was isolated at the
Hospital of theCatholicUniversity of Santiago in2007 fromapatient
who developed a wound infection. Diverse antibiotics were tested by
the disk diffusionmethod and by the agar dilution test, according to
the Clinical and Standards Institute (CLSI) guidelines (5). Ab5 was
found to be resistant to ceftazidime, imipenem, meropenem, genta-
micin, cefotaxime, ciprofloxacin, cefepime, and piperacillin-
tazobactam. TheMICs to carbapenemswere 8g/ml tomeropenem
and 16g/ml to imipenem.
WGS was performed utilizing the Illumina HiSeq 2000 plat-
form. The data generated were assembled using the Velvet assem-
bly pipeline (6), with contigs200 bp, resulting in 107 contigs, a
total length of 3,937,075 bp, and anN50 contig size of 173,003 bp;
meanwhile, the average GC content was 38.9%, coinciding with
the data associated with the Acinetobacter genus.
Genome annotation was performed utilizing the Rapid Anno-
tations using Subsystems Technology (RAST) (7), and the IGS
Annotation Engine was used for structural and functional anno-
tation (8). Manatee was used to view annotations (http://manatee
.sourceforge.net/), while ResFinder (9), PathogenFinder (10), and
multilocus sequence typing (MLST) of total genome-sequenced
bacteria (11) were utilized for complementary analyzes.
We identified 3,657 coding sequences (CDSs), 57 pseudogenes,
7 rRNAs, and 57 tRNAs. Additionally, Ab5 belonged to sequence
type 162 (ST-162), which was previously detected in Brazil. We
identified the blaOXA-58, blaOXA-51, aph(3=)-Via, and the DNA to-
poisomerase type II genes that might explain its MDR pheno-
type. Interestingly, we found genes associated with iron acqui-
sition, such as the pitADC, piaABC, and piuABC operons,
which have been identified in Streptococcus pneumoniae. We
also identified 25 pathogenesis-associated operons derived
from Mycobacterium spp., whereas one detected operon, in-
volved in internalin-like proteins synthesis, may have been im-
ported from Listeria.
This first approach reflects the ability of A. baumannii to cap-
ture a wide range of genes derived from different species, making
it a troublesome pathogen to treat in the nosocomial environ-
ment.
Nucleotide sequence accessionnumbers.Thiswhole-genome
shotgun project has been deposited at DDBJ/EMBL/GenBank un-
der the accession no. LANH00000000. The version described in
this paper is version LANH01000000.
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